Steven McNulty.

To permit the changeover from intravenous cangrelor to oral clopidogrel, patients received another four capsules at the discontinuation of the study-drug infusion. The duration of daily clopidogrel following the procedure was still left to the discretion of the treating physician, although additional clopidogrel beyond the recommended study medication had not been allowed before day following the index procedure. All patients received 75 to 325 mg of aspirin according to local-site specifications. Decisions about the use of adjunctive anticoagulants and the procedural use of glycoprotein IIb/IIIa inhibitors had been created by the treating physician. Efficacy End Points The principal efficacy end point of the analysis was the composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.A Phase I safety study in healthy male volunteers already demonstrated that solitary and multiple inhalations of the ALX-0171 had been well tolerated and no dose-limiting toxicity or treatment emergent immunogenicity was noticed. Furthermore, ALX-0171 acquired no clinically relevant effect on lung function, no symptoms of bronchoconstriction were observed, and the Nanobody provided the chance for once-daily dosing. Related StoriesNew vaccine applicant shows great promise at fighting respiratory syncytial virusMillions more bird species killed by West Nile virus than previously thoughtParatek initiates Omadacycline phase 3 clinical research in community obtained bacterial pneumonia ‘The outcomes achieved to time in the ALX-0171 development program by our partner Ablynx are very encouraging and represent further validation not only for Ablynx's unparalleled Nanobody technology, also for Activaero's FAVORITE inhalation strategy’, commented Gerhard Scheuch, Chief and Founder Executive Officer of Activaero GmbH.